Item 8.01 Other Events.

On January 30, 2020, FibroGen, Inc. and its collaboration partner, Astellas Pharma Inc., issued a press release in which they announced the submission of a supplemental New Drug Application to Japan's Ministry of Health for marketing approval for Evrenzo® (roxadustat) in Japan for the treatment of anemia associated with chronic kidney disease (CKD) in non-dialysis dependent patients. Roxadustat was approved in Japan for the treatment of anemia associated with CKD in dialysis dependent patients in September 2019.

A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d)  Exhibits

Exhibit No.    Description

99.1             Press Release titled "Astellas Submits Supplemental New Drug
               Application for Approval of Evrenzo® (roxadustat) for the Treatment of
               Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent
               Patients in Japan" dated January 30, 2020

104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses